
## Yair Molad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7482809/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Update on colchicine and its mechanism of action. Current Rheumatology Reports, 2002, 4, 252-256.	2.1	169
2	Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism, 1993, 36, 1111-1120.	6.7	168
3	Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis and Rheumatism, 2004, 50, 173-182.	6.7	135
4	Recurrent aphthous stomatitis in Behçet's disease: clinical featueres and correlation with systemic disease expression and severity. Journal of Oral Pathology and Medicine, 1999, 28, 193-196.	1.4	71
5	Intravascular Neutrophil Activation in Systemic Lupus Erythematosus (SLE): Dissociation between Increased Expression of CD11b/CD18 and Diminished Expression of L-Selectin on Neutrophils from Patients with Active SLE. Clinical Immunology and Immunopathology, 1994, 71, 281-286.	2.1	46
6	Renal outcome and vascular morbidity in systemic lupus erythematosus (SLE): Lack of association with the angiotensin-converting enzyme gene polymorphism. Seminars in Arthritis and Rheumatism, 2000, 30, 132-137.	1.6	42
7	Association of Low Serum Complement C3 with Reduced Patient and Renal Survival in Antimyeloperoxidase-Associated Small-Vessel Vasculitis. Nephron Clinical Practice, 2014, 126, 67-74.	2.3	34
8	Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clinical Rheumatology, 2014, 33, 649-657.	1.0	32
9	Hemophagocytosis by small cell lung carcinoma. American Journal of Hematology, 1991, 36, 154-156.	2.0	31
10	Serum Soluble Triggering Receptor on Myeloid Cells-1 (sTREM-1) is Elevated in Systemic Lupus Erythematosus but does not Distinguish Between Lupus Alone and Concurrent Infection. Inflammation, 2013, 36, 1519-1524.	1.7	31
11	The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. European Journal of Clinical Investigation, 2020, 50, e13268.	1.7	31
12	Connective tissue disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 463-473.	1.0	29
13	Adult-onset Still's disease following mRNA COVID-19 vaccination. Clinical Immunology, 2021, 233, 108878.	1.4	25
14	Heart valve calcification in young patients with systemic lupus erythematosus: A window to premature atherosclerotic vascular morbidity and a risk factor for all-cause mortality. Atherosclerosis, 2006, 185, 406-412.	0.4	24
15	Hematological Manifestations among Patients with Rheumatic Diseases. Acta Haematologica, 2021, 144, 403-412.	0.7	21
16	Controlled Ovarian Hyperstimulation: A State of Neutrophil Activation. American Journal of Reproductive Immunology, 1999, 42, 288-291.	1.2	20
17	CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immunity, 2013, 19, 623-630.	1.1	18
18	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Science and Medicine, 2022, 9, e000651.	1.1	18

YAIR MOLAD

#	Article	IF	CITATIONS
19	Soluble triggering receptor expressed on myeloid cellsâ€1 is a biomarker of antiâ€ <scp>CCP</scp> â€positive, early rheumatoid arthritis. European Journal of Clinical Investigation, 2015, 45, 557-564.	1.7	17
20	Systemic lupus erythematosus and pregnancy. Current Opinion in Obstetrics and Gynecology, 2006, 18, 613-617.	0.9	16
21	The safety of pulse corticosteroid therapy- Systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2020, 50, 534-545.	1.6	12
22	Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome. Arthritis Research and Therapy, 2019, 21, 10.	1.6	11
23	Incident gout and chronic Kidney Disease: healthcare utilization and survival. BMC Rheumatology, 2019, 3, 11.	0.6	9
24	Neutrophil Adhesion Molecule Expression in Familial Mediterranean Fever: Discordance between the Intravascular Regulation of β2 Integrin and L-Selectin Expression in Acute Attack. Journal of Investigative Medicine, 2004, 52, 58-61.	0.7	8
25	Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcare. Lupus, 2022, 31, 532-540.	0.8	8
26	Corneal melting in rheumatoid arthritis patients treated with a tectonic reinforcing corneolimbal graft: an interventional case series. International Ophthalmology, 2018, 38, 1317-1324.	0.6	5
27	Elevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome. Mediators of Inflammation, 2021, 2021, 1-9.	1.4	3
28	Anti-Ro/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis. Modern Rheumatology, 2022, 32, 1086-1093.	0.9	3
29	Guanine polynucleotides are selfâ€entigens for human natural autoantibodies and are significantly reduced in the human genome. Immunology, 2015, 146, 401-410.	2.0	2
30	Diffused coronary involvement in Takayasu arteritis with concomitant malignancy. Clinical Rheumatology, 2022, 41, 921-928.	1.0	2
31	Constitutively increased neutrophil surface expression of beta2-integrin in Yemenite Jews. Inflammation, 2003, 27, 301-305.	1.7	0
32	Response to the letter to the editor by Gkougkourelas etÂal – <scp>EJCl</scp> â€2017â€0361. European Journal of Clinical Investigation, 2017, 47, e12850.	1.7	0
33	Anti-CD20 Monoclonal Antibody (Rituximab) as an Optional Treatment for Intractable Acquired Glanzmann's Thrombasthenia Blood, 2006, 108, 3971-3971.	0.6	0